STOCK TITAN

Amylyx Pharmaceuticals Inc - AMLX STOCK NEWS

Welcome to our dedicated news page for Amylyx Pharmaceuticals (Ticker: AMLX), a resource for investors and traders seeking the latest updates and insights on Amylyx Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amylyx Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amylyx Pharmaceuticals's position in the market.

Rhea-AI Summary
Amylyx Pharmaceuticals announces publication of post hoc analysis in Annals of Clinical and Translational Neurology comparing long-term survival of participants in CENTAUR study
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
-
Rhea-AI Summary
ANSM grants compassionate access to AMX0035 for ALS patients in France.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
none
-
Rhea-AI Summary
Amylyx Pharmaceuticals announces acceptance of abstracts for presentation at the NEALS Annual Meeting, highlighting progress on AMX0035 and AMX0114 for ALS treatment. Updates include the development of a diagnostic biomarker test, targeting axonal degeneration, and evaluating neuroprotective strategies. Real-world experiences and safety data are also shared.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
Rhea-AI Summary
Amylyx Pharmaceuticals to participate in upcoming investor conferences in September
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
conferences
-
Rhea-AI Summary
Amylyx Pharmaceuticals reported strong financial results for the second quarter of 2023, with product revenue of $98.2 million and net income of $22.1 million. The company's commercial launches of RELYVRIO in the U.S. and ALBRIOZA in Canada continued to progress, and five Canadian provinces announced public reimbursement for ALBRIOZA. Amylyx also plans to initiate a global Phase 3 trial of AMX0035 for the treatment of progressive supranuclear palsy later this year. Additionally, the Marketing Authorisation Application for AMX0035 for the treatment of ALS is under review with the European Medicines Agency's Committee for Medicinal Products for Human Use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
-
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) will report its second quarter 2023 financial results on August 10, 2023, followed by a conference call and webcast to discuss the results and company updates. Investors can access the call and webcast through the company's website or by dialing the provided numbers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
conferences earnings
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) announced a virtual webcast with Prof. Dr. Günter Höglinger to discuss the treatment landscape for progressive supranuclear palsy (PSP) and the Company’s clinical development plans for AMX0035 in PSP on July 26, 2023 at 1:30pm ET. Prof. Dr. Höglinger is an expert in neurodegenerative Parkinson syndromes and has been involved in international clinical trials in PSP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
conferences
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences
Amylyx Pharmaceuticals Inc

Nasdaq:AMLX

AMLX Rankings

AMLX Stock Data

136.24M
50.94M
14.24%
104.79%
8.86%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Cambridge

About AMLX

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.